 Martin McCarter
Concepts (810)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 52 | 2025 | 806 | 7.690 |
Why?
| | Esophageal Neoplasms | 29 | 2025 | 347 | 5.180 |
Why?
| | Skin Neoplasms | 34 | 2024 | 860 | 4.550 |
Why?
| | Adenocarcinoma | 29 | 2025 | 927 | 3.340 |
Why?
| | Esophagectomy | 20 | 2024 | 135 | 3.330 |
Why?
| | Myeloid-Derived Suppressor Cells | 6 | 2025 | 71 | 2.610 |
Why?
| | Sentinel Lymph Node Biopsy | 23 | 2022 | 120 | 2.570 |
Why?
| | Gastrointestinal Stromal Tumors | 10 | 2022 | 40 | 2.120 |
Why?
| | Neoadjuvant Therapy | 15 | 2025 | 461 | 1.650 |
Why?
| | Sentinel Lymph Node | 9 | 2022 | 49 | 1.620 |
Why?
| | Rectal Neoplasms | 8 | 2024 | 155 | 1.600 |
Why?
| | T-Lymphocytes, Regulatory | 11 | 2022 | 392 | 1.570 |
Why?
| | Dendritic Cells | 13 | 2019 | 495 | 1.560 |
Why?
| | Pancreatic Neoplasms | 15 | 2024 | 927 | 1.530 |
Why?
| | Neoplasm Recurrence, Local | 19 | 2024 | 1123 | 1.480 |
Why?
| | Stomach Neoplasms | 6 | 2025 | 125 | 1.410 |
Why?
| | Lymphatic Metastasis | 20 | 2023 | 333 | 1.310 |
Why?
| | Neoplasm Staging | 33 | 2025 | 1453 | 1.280 |
Why?
| | Tumor Escape | 4 | 2017 | 50 | 1.160 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 1938 | 1.140 |
Why?
| | Humans | 218 | 2026 | 143817 | 1.090 |
Why?
| | Hyperthermia, Induced | 4 | 2020 | 121 | 1.090 |
Why?
| | Sarcoma | 8 | 2026 | 203 | 1.090 |
Why?
| | Colonic Neoplasms | 7 | 2024 | 262 | 1.070 |
Why?
| | HIV-1 | 17 | 2025 | 904 | 1.060 |
Why?
| | Lymph Nodes | 15 | 2023 | 502 | 1.050 |
Why?
| | Middle Aged | 107 | 2026 | 35629 | 1.050 |
Why?
| | Anus Neoplasms | 3 | 2024 | 33 | 1.030 |
Why?
| | Neoplasms | 14 | 2025 | 2902 | 1.020 |
Why?
| | Aged | 89 | 2026 | 25616 | 1.010 |
Why?
| | Peritoneal Neoplasms | 4 | 2024 | 103 | 0.980 |
Why?
| | Postoperative Complications | 21 | 2025 | 2894 | 0.970 |
Why?
| | Retrospective Studies | 57 | 2026 | 16755 | 0.960 |
Why?
| | Hyperglycemia | 3 | 2020 | 370 | 0.960 |
Why?
| | Intestinal Neoplasms | 2 | 2024 | 30 | 0.950 |
Why?
| | HIV Infections | 21 | 2025 | 3048 | 0.930 |
Why?
| | Cytoreduction Surgical Procedures | 5 | 2024 | 68 | 0.930 |
Why?
| | Prognosis | 30 | 2025 | 4211 | 0.900 |
Why?
| | CD4-Positive T-Lymphocytes | 14 | 2025 | 1133 | 0.900 |
Why?
| | Laparoscopy | 8 | 2024 | 476 | 0.880 |
Why?
| | Colorectal Neoplasms | 8 | 2025 | 848 | 0.880 |
Why?
| | Intestine, Small | 2 | 2024 | 166 | 0.850 |
Why?
| | Survival Rate | 23 | 2025 | 2035 | 0.850 |
Why?
| | Male | 121 | 2026 | 71568 | 0.840 |
Why?
| | Female | 132 | 2026 | 77569 | 0.830 |
Why?
| | Mucosal-Associated Invariant T Cells | 1 | 2024 | 37 | 0.810 |
Why?
| | Intestinal Mucosa | 10 | 2021 | 665 | 0.790 |
Why?
| | Pancreaticoduodenectomy | 7 | 2021 | 130 | 0.750 |
Why?
| | Lymph Node Excision | 8 | 2022 | 173 | 0.740 |
Why?
| | Tretinoin | 3 | 2023 | 124 | 0.730 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 102 | 0.710 |
Why?
| | Lymphocyte Activation | 11 | 2018 | 1143 | 0.690 |
Why?
| | T-Lymphocytes | 8 | 2024 | 2041 | 0.680 |
Why?
| | Pelvic Exenteration | 4 | 2019 | 12 | 0.670 |
Why?
| | Gastrointestinal Microbiome | 9 | 2025 | 746 | 0.670 |
Why?
| | Proto-Oncogene Proteins c-kit | 5 | 2022 | 72 | 0.660 |
Why?
| | Radiosurgery | 4 | 2020 | 390 | 0.640 |
Why?
| | Adult | 69 | 2026 | 40128 | 0.630 |
Why?
| | Anastomotic Leak | 4 | 2024 | 45 | 0.630 |
Why?
| | Survival Analysis | 16 | 2022 | 1358 | 0.630 |
Why?
| | Splenectomy | 1 | 2020 | 64 | 0.620 |
Why?
| | Chemoradiotherapy | 6 | 2024 | 235 | 0.610 |
Why?
| | Pancreatic Cyst | 2 | 2017 | 50 | 0.600 |
Why?
| | Ipilimumab | 2 | 2019 | 39 | 0.590 |
Why?
| | Myeloid Cells | 3 | 2020 | 148 | 0.590 |
Why?
| | Piperazines | 5 | 2014 | 394 | 0.580 |
Why?
| | Ischemic Preconditioning | 3 | 2024 | 47 | 0.580 |
Why?
| | Spleen | 6 | 2017 | 517 | 0.580 |
Why?
| | Radiotherapy, Intensity-Modulated | 2 | 2018 | 141 | 0.570 |
Why?
| | Granulocytes | 2 | 2017 | 81 | 0.570 |
Why?
| | Pyrimidines | 5 | 2014 | 536 | 0.550 |
Why?
| | Induction Chemotherapy | 3 | 2024 | 86 | 0.540 |
Why?
| | Leukocytes, Mononuclear | 5 | 2021 | 580 | 0.540 |
Why?
| | Monocytes | 2 | 2020 | 543 | 0.540 |
Why?
| | Appendiceal Neoplasms | 1 | 2017 | 28 | 0.530 |
Why?
| | Antineoplastic Agents | 9 | 2024 | 2220 | 0.530 |
Why?
| | Aged, 80 and over | 28 | 2024 | 8130 | 0.520 |
Why?
| | Combined Modality Therapy | 15 | 2024 | 1261 | 0.510 |
Why?
| | Pylorus | 1 | 2017 | 18 | 0.510 |
Why?
| | Gastric Outlet Obstruction | 1 | 2017 | 12 | 0.510 |
Why?
| | Time-to-Treatment | 4 | 2025 | 235 | 0.510 |
Why?
| | Follow-Up Studies | 20 | 2025 | 5317 | 0.500 |
Why?
| | Mucous Membrane | 5 | 2024 | 128 | 0.500 |
Why?
| | CD8-Positive T-Lymphocytes | 6 | 2024 | 945 | 0.490 |
Why?
| | Soft Tissue Neoplasms | 3 | 2022 | 127 | 0.480 |
Why?
| | Neuromuscular Agents | 1 | 2017 | 45 | 0.480 |
Why?
| | Treatment Outcome | 29 | 2026 | 11459 | 0.470 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2018 | 199 | 0.470 |
Why?
| | Botulinum Toxins, Type A | 1 | 2017 | 57 | 0.470 |
Why?
| | Head and Neck Neoplasms | 5 | 2019 | 560 | 0.470 |
Why?
| | Leucovorin | 2 | 2019 | 100 | 0.470 |
Why?
| | Liver Neoplasms | 6 | 2024 | 774 | 0.450 |
Why?
| | Vitamin B Complex | 1 | 2014 | 40 | 0.430 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 5 | 2024 | 219 | 0.420 |
Why?
| | Immune Tolerance | 4 | 2016 | 378 | 0.420 |
Why?
| | Salvage Therapy | 2 | 2014 | 156 | 0.410 |
Why?
| | Esophagogastric Junction | 4 | 2024 | 55 | 0.410 |
Why?
| | Pancreatectomy | 5 | 2024 | 274 | 0.410 |
Why?
| | Minimally Invasive Surgical Procedures | 6 | 2023 | 191 | 0.400 |
Why?
| | Lymphocytes | 3 | 2021 | 395 | 0.400 |
Why?
| | Melanoma, Experimental | 3 | 2022 | 112 | 0.400 |
Why?
| | Pelvis | 1 | 2014 | 124 | 0.400 |
Why?
| | Ear, External | 1 | 2013 | 21 | 0.390 |
Why?
| | Mohs Surgery | 1 | 2013 | 29 | 0.390 |
Why?
| | Up-Regulation | 5 | 2025 | 863 | 0.390 |
Why?
| | Mutation | 9 | 2025 | 4106 | 0.390 |
Why?
| | T-Lymphocytes, Helper-Inducer | 4 | 2017 | 135 | 0.380 |
Why?
| | B-Lymphocytes | 4 | 2025 | 889 | 0.380 |
Why?
| | Immunity, Innate | 5 | 2025 | 853 | 0.370 |
Why?
| | Biopsy | 3 | 2023 | 1068 | 0.370 |
Why?
| | Prospective Studies | 22 | 2025 | 7900 | 0.370 |
Why?
| | Abdominal Neoplasms | 3 | 2025 | 47 | 0.370 |
Why?
| | Microbiota | 5 | 2024 | 781 | 0.360 |
Why?
| | Retroperitoneal Neoplasms | 4 | 2026 | 28 | 0.360 |
Why?
| | Tumor Microenvironment | 7 | 2025 | 738 | 0.360 |
Why?
| | Hematologic Diseases | 1 | 2012 | 68 | 0.360 |
Why?
| | Anastomosis, Surgical | 3 | 2024 | 156 | 0.360 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2014 | 646 | 0.360 |
Why?
| | Suppressor Factors, Immunologic | 1 | 2011 | 4 | 0.350 |
Why?
| | Receptors, CCR5 | 3 | 2021 | 61 | 0.350 |
Why?
| | Biomarkers, Tumor | 6 | 2025 | 1327 | 0.350 |
Why?
| | Cytokines | 8 | 2021 | 2093 | 0.340 |
Why?
| | Cell Movement | 6 | 2025 | 973 | 0.340 |
Why?
| | Dasatinib | 2 | 2024 | 61 | 0.340 |
Why?
| | Surgical Wound Infection | 1 | 2014 | 327 | 0.340 |
Why?
| | Palliative Care | 1 | 2019 | 982 | 0.330 |
Why?
| | Conversion to Open Surgery | 2 | 2020 | 22 | 0.320 |
Why?
| | Granzymes | 2 | 2021 | 50 | 0.320 |
Why?
| | Killer Cells, Natural | 3 | 2025 | 473 | 0.320 |
Why?
| | Thrombelastography | 2 | 2024 | 178 | 0.320 |
Why?
| | Esophageal Achalasia | 2 | 2021 | 28 | 0.310 |
Why?
| | Homosexuality, Male | 3 | 2021 | 215 | 0.310 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2022 | 127 | 0.310 |
Why?
| | Benzamides | 5 | 2014 | 225 | 0.310 |
Why?
| | Young Adult | 20 | 2025 | 13914 | 0.310 |
Why?
| | Databases, Factual | 7 | 2025 | 1459 | 0.300 |
Why?
| | Interferon-gamma | 6 | 2019 | 791 | 0.300 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 2 | 2019 | 15 | 0.290 |
Why?
| | Immunotherapy | 5 | 2024 | 669 | 0.290 |
Why?
| | Membrane Glycoproteins | 3 | 2015 | 499 | 0.280 |
Why?
| | Butyrates | 2 | 2021 | 67 | 0.280 |
Why?
| | Medical Oncology | 4 | 2022 | 327 | 0.280 |
Why?
| | Barrett Esophagus | 3 | 2020 | 165 | 0.280 |
Why?
| | Interleukin-15 | 2 | 2021 | 99 | 0.280 |
Why?
| | Immunity, Mucosal | 3 | 2016 | 99 | 0.280 |
Why?
| | Chemotherapy, Adjuvant | 9 | 2023 | 409 | 0.280 |
Why?
| | Wounds and Injuries | 4 | 2009 | 949 | 0.270 |
Why?
| | Cell Differentiation | 5 | 2016 | 2045 | 0.270 |
Why?
| | Neoplasm Metastasis | 4 | 2025 | 704 | 0.270 |
Why?
| | Interleukin-10 | 4 | 2025 | 311 | 0.270 |
Why?
| | Inflammation Mediators | 2 | 2018 | 511 | 0.270 |
Why?
| | Disease-Free Survival | 8 | 2019 | 767 | 0.270 |
Why?
| | Blood Preservation | 2 | 2009 | 353 | 0.260 |
Why?
| | Nomograms | 2 | 2019 | 58 | 0.260 |
Why?
| | Antigens, Neoplasm | 3 | 2024 | 328 | 0.260 |
Why?
| | Prostatic Neoplasms | 1 | 2014 | 977 | 0.260 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 12 | 0.260 |
Why?
| | General Surgery | 2 | 2007 | 205 | 0.260 |
Why?
| | Immunocompromised Host | 1 | 2008 | 201 | 0.250 |
Why?
| | Dysbiosis | 3 | 2021 | 186 | 0.250 |
Why?
| | Colon | 3 | 2021 | 303 | 0.250 |
Why?
| | Cells, Cultured | 9 | 2021 | 4172 | 0.250 |
Why?
| | Mice | 25 | 2025 | 18421 | 0.250 |
Why?
| | Splenic Neoplasms | 1 | 2006 | 4 | 0.240 |
Why?
| | Lymphangioma | 1 | 2006 | 9 | 0.240 |
Why?
| | Forkhead Transcription Factors | 1 | 2007 | 205 | 0.240 |
Why?
| | Time Factors | 12 | 2024 | 7068 | 0.240 |
Why?
| | Erythrocyte Transfusion | 1 | 2008 | 228 | 0.240 |
Why?
| | Th2 Cells | 2 | 2005 | 183 | 0.240 |
Why?
| | Pelvic Neoplasms | 3 | 2012 | 24 | 0.240 |
Why?
| | Population Surveillance | 2 | 2021 | 491 | 0.240 |
Why?
| | Transplantation Immunology | 1 | 2005 | 29 | 0.230 |
Why?
| | Ecotype | 1 | 2025 | 16 | 0.230 |
Why?
| | Receptors, Cell Surface | 2 | 2021 | 380 | 0.230 |
Why?
| | Macrophages, Peritoneal | 3 | 2005 | 89 | 0.230 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2025 | 48 | 0.230 |
Why?
| | Interleukin-1 Receptor-Associated Kinases | 1 | 2025 | 37 | 0.230 |
Why?
| | Mice, Inbred BALB C | 6 | 2024 | 1270 | 0.230 |
Why?
| | Vena Cava, Inferior | 1 | 2026 | 82 | 0.230 |
Why?
| | Exome | 2 | 2017 | 239 | 0.230 |
Why?
| | Signal Transduction | 10 | 2025 | 5241 | 0.230 |
Why?
| | Mentors | 1 | 2007 | 214 | 0.230 |
Why?
| | Nevus, Epithelioid and Spindle Cell | 1 | 2005 | 14 | 0.230 |
Why?
| | Neuroendocrine Tumors | 2 | 2017 | 111 | 0.230 |
Why?
| | Circulating Tumor DNA | 1 | 2025 | 44 | 0.230 |
Why?
| | Catheter Ablation | 4 | 2016 | 351 | 0.220 |
Why?
| | Cellular Microenvironment | 1 | 2025 | 93 | 0.220 |
Why?
| | Computational Biology | 3 | 2025 | 683 | 0.220 |
Why?
| | DNA-Activated Protein Kinase | 1 | 2024 | 15 | 0.220 |
Why?
| | Culture Media, Conditioned | 4 | 2011 | 111 | 0.220 |
Why?
| | Radiation Injuries | 2 | 2021 | 147 | 0.220 |
Why?
| | Tumor Hypoxia | 1 | 2024 | 8 | 0.220 |
Why?
| | Gastrectomy | 3 | 2025 | 150 | 0.220 |
Why?
| | Nevus, Pigmented | 1 | 2005 | 35 | 0.220 |
Why?
| | Metastasectomy | 1 | 2024 | 22 | 0.210 |
Why?
| | Th1 Cells | 2 | 2019 | 142 | 0.210 |
Why?
| | Virus Replication | 5 | 2017 | 537 | 0.210 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2021 | 307 | 0.210 |
Why?
| | Macrophage Activation | 1 | 2005 | 192 | 0.210 |
Why?
| | Hepatectomy | 3 | 2024 | 268 | 0.210 |
Why?
| | Lymphangiogenesis | 1 | 2004 | 26 | 0.210 |
Why?
| | Interferon-alpha | 3 | 2015 | 184 | 0.210 |
Why?
| | Mice, Nude | 2 | 2024 | 692 | 0.210 |
Why?
| | Cohort Studies | 7 | 2025 | 5862 | 0.210 |
Why?
| | B7-H1 Antigen | 2 | 2024 | 246 | 0.210 |
Why?
| | Lymphocyte Count | 5 | 2017 | 168 | 0.200 |
Why?
| | Carcinoma | 2 | 2006 | 230 | 0.200 |
Why?
| | Ruminococcus | 2 | 2021 | 8 | 0.200 |
Why?
| | In Vitro Techniques | 5 | 2019 | 1054 | 0.200 |
Why?
| | Pseudomonas Infections | 1 | 2025 | 218 | 0.200 |
Why?
| | Esophageal Stenosis | 1 | 2024 | 55 | 0.200 |
Why?
| | Paget Disease, Extramammary | 1 | 2003 | 4 | 0.200 |
Why?
| | Enterobacteriaceae | 2 | 2017 | 43 | 0.200 |
Why?
| | Flow Cytometry | 6 | 2017 | 1192 | 0.200 |
Why?
| | Immunophenotyping | 3 | 2025 | 327 | 0.200 |
Why?
| | Cannabinoids | 1 | 2025 | 178 | 0.200 |
Why?
| | Feces | 4 | 2021 | 506 | 0.200 |
Why?
| | Erythrocytes | 1 | 2009 | 757 | 0.190 |
Why?
| | Adolescent | 15 | 2019 | 22233 | 0.190 |
Why?
| | Lymphoscintigraphy | 2 | 2019 | 10 | 0.190 |
Why?
| | Animals | 28 | 2025 | 38140 | 0.190 |
Why?
| | Lysophospholipids | 1 | 2023 | 74 | 0.190 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2022 | 232 | 0.190 |
Why?
| | Specialties, Surgical | 1 | 2023 | 79 | 0.190 |
Why?
| | Lymphoid Tissue | 3 | 2008 | 80 | 0.190 |
Why?
| | Intestines | 2 | 2017 | 354 | 0.190 |
Why?
| | Protein-Energy Malnutrition | 2 | 2003 | 6 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 97 | 0.190 |
Why?
| | Transforming Growth Factor beta | 4 | 2015 | 481 | 0.190 |
Why?
| | Cell Count | 2 | 2017 | 324 | 0.190 |
Why?
| | Education, Medical, Graduate | 1 | 2007 | 548 | 0.180 |
Why?
| | Salmonella typhimurium | 2 | 2021 | 191 | 0.180 |
Why?
| | Cryosurgery | 2 | 2019 | 47 | 0.180 |
Why?
| | Ampulla of Vater | 2 | 2024 | 36 | 0.180 |
Why?
| | Receptors, CXCR3 | 1 | 2022 | 16 | 0.180 |
Why?
| | Preoperative Care | 3 | 2018 | 376 | 0.180 |
Why?
| | HIV Seropositivity | 1 | 2022 | 118 | 0.180 |
Why?
| | Chemokine CXCL9 | 1 | 2022 | 38 | 0.180 |
Why?
| | Patient Selection | 3 | 2014 | 695 | 0.180 |
Why?
| | Chemokine CXCL10 | 1 | 2022 | 40 | 0.180 |
Why?
| | Imatinib Mesylate | 5 | 2014 | 79 | 0.180 |
Why?
| | Bacteria | 3 | 2018 | 888 | 0.180 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 162 | 0.180 |
Why?
| | Cell Line, Tumor | 7 | 2025 | 3609 | 0.180 |
Why?
| | Tomography, X-Ray Computed | 6 | 2016 | 2782 | 0.170 |
Why?
| | Esophagoscopy | 2 | 2020 | 218 | 0.170 |
Why?
| | Acinetobacter | 1 | 2021 | 15 | 0.170 |
Why?
| | Critical Pathways | 1 | 2022 | 107 | 0.170 |
Why?
| | Germinal Center | 2 | 2025 | 67 | 0.170 |
Why?
| | Carcinoma in Situ | 1 | 2001 | 44 | 0.170 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2022 | 178 | 0.170 |
Why?
| | Seminoma | 1 | 2021 | 20 | 0.170 |
Why?
| | ADAM10 Protein | 1 | 2021 | 29 | 0.170 |
Why?
| | Social Determinants of Health | 1 | 2025 | 294 | 0.170 |
Why?
| | Glucose | 3 | 2020 | 1041 | 0.170 |
Why?
| | Disease Progression | 2 | 2022 | 2871 | 0.170 |
Why?
| | Gamma Rays | 1 | 2021 | 58 | 0.170 |
Why?
| | Carcinoma, Lobular | 1 | 2001 | 56 | 0.160 |
Why?
| | Risk Factors | 12 | 2024 | 10623 | 0.160 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 684 | 0.160 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 2001 | 89 | 0.160 |
Why?
| | Interleukin-2 | 5 | 2022 | 447 | 0.160 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 77 | 0.160 |
Why?
| | Diarrhea | 3 | 2008 | 188 | 0.160 |
Why?
| | Group II Phospholipases A2 | 1 | 2020 | 10 | 0.160 |
Why?
| | Delivery of Health Care | 2 | 2021 | 946 | 0.160 |
Why?
| | Bacterial Translocation | 2 | 2019 | 52 | 0.160 |
Why?
| | Receptors, CCR | 1 | 2020 | 6 | 0.160 |
Why?
| | Transcriptome | 2 | 2025 | 1047 | 0.160 |
Why?
| | Carcinoembryonic Antigen | 2 | 2022 | 38 | 0.160 |
Why?
| | Interleukins | 2 | 2019 | 252 | 0.160 |
Why?
| | Platelet Count | 1 | 2020 | 89 | 0.160 |
Why?
| | Software | 1 | 2025 | 690 | 0.160 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2021 | 76 | 0.160 |
Why?
| | Guidelines as Topic | 2 | 2018 | 270 | 0.160 |
Why?
| | Basophils | 1 | 2020 | 53 | 0.150 |
Why?
| | Protein Kinase Inhibitors | 4 | 2024 | 1000 | 0.150 |
Why?
| | Apoptosis | 5 | 2021 | 2446 | 0.150 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 87 | 0.150 |
Why?
| | Neutrophils | 1 | 2025 | 1144 | 0.150 |
Why?
| | United States | 14 | 2025 | 15602 | 0.150 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 219 | 0.150 |
Why?
| | Dacarbazine | 4 | 2012 | 97 | 0.150 |
Why?
| | Cell Proliferation | 6 | 2021 | 2540 | 0.150 |
Why?
| | Scalp | 1 | 2019 | 38 | 0.150 |
Why?
| | Sclerosing Solutions | 1 | 2019 | 10 | 0.150 |
Why?
| | Argon Plasma Coagulation | 1 | 2019 | 6 | 0.150 |
Why?
| | Leukocyte Count | 1 | 2020 | 317 | 0.150 |
Why?
| | Gastric Bypass | 1 | 2021 | 123 | 0.150 |
Why?
| | Germ-Free Life | 1 | 2019 | 33 | 0.150 |
Why?
| | Sclerotherapy | 1 | 2019 | 19 | 0.150 |
Why?
| | Palatine Tonsil | 4 | 2025 | 56 | 0.150 |
Why?
| | CD4 Antigens | 2 | 2011 | 144 | 0.150 |
Why?
| | Haploinsufficiency | 1 | 2019 | 55 | 0.150 |
Why?
| | Patient Care Planning | 2 | 2016 | 167 | 0.150 |
Why?
| | Stomach | 3 | 2024 | 109 | 0.150 |
Why?
| | Self Expandable Metallic Stents | 1 | 2019 | 17 | 0.150 |
Why?
| | Mastocytosis | 1 | 2019 | 12 | 0.150 |
Why?
| | Nutritional Support | 1 | 2019 | 38 | 0.150 |
Why?
| | Surgeons | 1 | 2023 | 336 | 0.150 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2022 | 54 | 0.150 |
Why?
| | HLA-DR Antigens | 2 | 2011 | 219 | 0.150 |
Why?
| | Gram-Positive Bacteria | 1 | 2019 | 48 | 0.150 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 224 | 0.150 |
Why?
| | Photochemotherapy | 1 | 2019 | 39 | 0.150 |
Why?
| | Intestinal Perforation | 1 | 2019 | 45 | 0.140 |
Why?
| | Postoperative Period | 1 | 2020 | 353 | 0.140 |
Why?
| | Decision Making | 2 | 2019 | 966 | 0.140 |
Why?
| | Environmental Restoration and Remediation | 1 | 2018 | 9 | 0.140 |
Why?
| | Skin Pigmentation | 1 | 2019 | 48 | 0.140 |
Why?
| | Dilatation | 1 | 2019 | 70 | 0.140 |
Why?
| | Gram-Negative Bacteria | 1 | 2019 | 79 | 0.140 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 107 | 0.140 |
Why?
| | Th17 Cells | 1 | 2019 | 104 | 0.140 |
Why?
| | Intestinal Obstruction | 1 | 2019 | 56 | 0.140 |
Why?
| | Esophagus | 1 | 2020 | 259 | 0.140 |
Why?
| | Survivors | 2 | 2015 | 513 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2025 | 1496 | 0.140 |
Why?
| | Fibrosis | 1 | 2021 | 547 | 0.140 |
Why?
| | Tissue and Organ Procurement | 1 | 2022 | 336 | 0.140 |
Why?
| | Breast Neoplasms | 2 | 2001 | 2497 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.140 |
Why?
| | Brachytherapy | 1 | 2019 | 130 | 0.140 |
Why?
| | Hospitals | 2 | 2021 | 695 | 0.140 |
Why?
| | Germ-Line Mutation | 1 | 2019 | 173 | 0.140 |
Why?
| | Oncogene Proteins v-abl | 1 | 2017 | 6 | 0.140 |
Why?
| | HIV | 1 | 2019 | 248 | 0.130 |
Why?
| | Down-Regulation | 1 | 2020 | 641 | 0.130 |
Why?
| | Risk Assessment | 4 | 2024 | 3556 | 0.130 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2018 | 33 | 0.130 |
Why?
| | Carcinoid Tumor | 1 | 2017 | 21 | 0.130 |
Why?
| | Viral Tropism | 1 | 2017 | 36 | 0.130 |
Why?
| | Food, Formulated | 1 | 1997 | 15 | 0.130 |
Why?
| | Neurofibromin 1 | 1 | 2017 | 26 | 0.130 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2017 | 24 | 0.130 |
Why?
| | Deglutition Disorders | 1 | 2019 | 149 | 0.130 |
Why?
| | Laser Therapy | 1 | 2019 | 136 | 0.130 |
Why?
| | Liver | 4 | 2016 | 1846 | 0.130 |
Why?
| | Venous Thromboembolism | 2 | 2012 | 330 | 0.130 |
Why?
| | src-Family Kinases | 1 | 2017 | 99 | 0.130 |
Why?
| | Fatty Acids, Omega-3 | 1 | 1998 | 142 | 0.130 |
Why?
| | Gastric Emptying | 1 | 2017 | 37 | 0.130 |
Why?
| | Chemotaxis, Leukocyte | 2 | 2025 | 115 | 0.130 |
Why?
| | Enteral Nutrition | 2 | 2010 | 213 | 0.130 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 63 | 0.130 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2019 | 233 | 0.130 |
Why?
| | Disease Management | 1 | 2021 | 639 | 0.130 |
Why?
| | Arginine | 1 | 1998 | 265 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 982 | 0.130 |
Why?
| | Analgesics, Opioid | 1 | 2025 | 1135 | 0.120 |
Why?
| | Digestive System Neoplasms | 1 | 2016 | 9 | 0.120 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2018 | 210 | 0.120 |
Why?
| | Hospitals, High-Volume | 1 | 2016 | 48 | 0.120 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 832 | 0.120 |
Why?
| | Nutritional Status | 1 | 2019 | 351 | 0.120 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2018 | 230 | 0.120 |
Why?
| | Cancer Care Facilities | 1 | 2016 | 48 | 0.120 |
Why?
| | Genes, erbB-1 | 1 | 2016 | 21 | 0.120 |
Why?
| | Antigen Presentation | 1 | 2017 | 215 | 0.120 |
Why?
| | Polysaccharides, Bacterial | 1 | 2016 | 67 | 0.120 |
Why?
| | Digestive System Surgical Procedures | 1 | 1997 | 103 | 0.120 |
Why?
| | Bystander Effect | 1 | 2016 | 19 | 0.120 |
Why?
| | Immunologic Memory | 2 | 2016 | 375 | 0.120 |
Why?
| | Predictive Value of Tests | 6 | 2024 | 2097 | 0.120 |
Why?
| | Lymphocyte Depletion | 3 | 2013 | 135 | 0.120 |
Why?
| | Genital Neoplasms, Female | 1 | 2017 | 96 | 0.120 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 28 | 0.120 |
Why?
| | Mortality | 1 | 2018 | 362 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 2 | 2024 | 421 | 0.120 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2016 | 101 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 238 | 0.120 |
Why?
| | Morbidity | 3 | 2023 | 322 | 0.110 |
Why?
| | Exons | 3 | 2019 | 358 | 0.110 |
Why?
| | Cystadenoma, Mucinous | 1 | 2015 | 11 | 0.110 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2015 | 57 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 856 | 0.110 |
Why?
| | Cystadenocarcinoma, Mucinous | 1 | 2015 | 12 | 0.110 |
Why?
| | Perioperative Care | 1 | 2018 | 223 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2002 | 1688 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1223 | 0.110 |
Why?
| | Postoperative Care | 1 | 1997 | 278 | 0.110 |
Why?
| | Adenoma | 1 | 2017 | 218 | 0.110 |
Why?
| | Ileus | 1 | 2014 | 13 | 0.110 |
Why?
| | Receptors, Ghrelin | 1 | 2014 | 8 | 0.110 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2015 | 92 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2025 | 559 | 0.110 |
Why?
| | Phosphoproteins | 1 | 2017 | 348 | 0.110 |
Why?
| | Biomarkers | 3 | 2024 | 4248 | 0.110 |
Why?
| | Vinblastine | 2 | 2012 | 74 | 0.110 |
Why?
| | Viral Load | 5 | 2018 | 515 | 0.110 |
Why?
| | Endosonography | 1 | 2016 | 157 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2021 | 945 | 0.110 |
Why?
| | Ethanol | 1 | 2019 | 626 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2021 | 1182 | 0.100 |
Why?
| | Quality of Life | 3 | 2019 | 3141 | 0.100 |
Why?
| | Tumor Cells, Cultured | 4 | 2021 | 944 | 0.100 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 65 | 0.100 |
Why?
| | Dietary Supplements | 1 | 1998 | 576 | 0.100 |
Why?
| | Blood Cell Count | 1 | 2013 | 53 | 0.100 |
Why?
| | Fluorouracil | 2 | 2019 | 234 | 0.100 |
Why?
| | Tumor Burden | 4 | 2022 | 321 | 0.100 |
Why?
| | Lung Neoplasms | 2 | 2017 | 2636 | 0.100 |
Why?
| | Colectomy | 3 | 2008 | 107 | 0.100 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 204 | 0.100 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2013 | 89 | 0.100 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2016 | 897 | 0.100 |
Why?
| | RNA, Viral | 3 | 2013 | 690 | 0.100 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2016 | 370 | 0.100 |
Why?
| | Pilot Projects | 1 | 2018 | 1851 | 0.090 |
Why?
| | Anti-Inflammatory Agents | 1 | 2016 | 483 | 0.090 |
Why?
| | Oligopeptides | 1 | 2014 | 267 | 0.090 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2013 | 77 | 0.090 |
Why?
| | Sensitivity and Specificity | 4 | 2015 | 1984 | 0.090 |
Why?
| | Side-Population Cells | 1 | 2012 | 8 | 0.090 |
Why?
| | Chi-Square Distribution | 3 | 2014 | 516 | 0.090 |
Why?
| | HIV Antibodies | 1 | 2013 | 67 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2407 | 0.090 |
Why?
| | Ablation Techniques | 1 | 2012 | 36 | 0.090 |
Why?
| | Cisplatin | 2 | 2012 | 338 | 0.090 |
Why?
| | Biological Therapy | 1 | 2012 | 27 | 0.090 |
Why?
| | Mice, Knockout | 4 | 2024 | 3120 | 0.090 |
Why?
| | Registries | 1 | 2021 | 2242 | 0.090 |
Why?
| | Hospital Mortality | 2 | 2016 | 975 | 0.090 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2012 | 99 | 0.090 |
Why?
| | Efficiency, Organizational | 1 | 2013 | 135 | 0.090 |
Why?
| | Tertiary Care Centers | 1 | 2013 | 186 | 0.090 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2011 | 43 | 0.090 |
Why?
| | Escherichia coli Infections | 1 | 2012 | 128 | 0.090 |
Why?
| | Elective Surgical Procedures | 1 | 2013 | 196 | 0.090 |
Why?
| | RNA, Ribosomal, 16S | 3 | 2019 | 561 | 0.090 |
Why?
| | Colonic Pouches | 1 | 2011 | 14 | 0.090 |
Why?
| | Proctocolectomy, Restorative | 1 | 2011 | 23 | 0.090 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 190 | 0.090 |
Why?
| | Gene Expression Profiling | 3 | 2025 | 1817 | 0.080 |
Why?
| | Macrophages | 2 | 2001 | 1508 | 0.080 |
Why?
| | Ligands | 2 | 2023 | 674 | 0.080 |
Why?
| | Multivariate Analysis | 4 | 2016 | 1508 | 0.080 |
Why?
| | Extremities | 2 | 2022 | 141 | 0.080 |
Why?
| | Cell Separation | 2 | 2010 | 311 | 0.080 |
Why?
| | Patient Care Team | 1 | 2016 | 676 | 0.080 |
Why?
| | Endocytosis | 1 | 2011 | 171 | 0.080 |
Why?
| | Toll-Like Receptor 8 | 1 | 2010 | 8 | 0.080 |
Why?
| | DNA Copy Number Variations | 2 | 2025 | 185 | 0.080 |
Why?
| | Interleukin-23 | 1 | 2010 | 16 | 0.080 |
Why?
| | Heparin | 1 | 2012 | 250 | 0.080 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2012 | 342 | 0.080 |
Why?
| | Toll-Like Receptor 7 | 1 | 2010 | 42 | 0.080 |
Why?
| | Gastric Fistula | 1 | 2010 | 9 | 0.080 |
Why?
| | Cutaneous Fistula | 1 | 2010 | 14 | 0.080 |
Why?
| | Antibodies, Neutralizing | 1 | 2013 | 344 | 0.080 |
Why?
| | Antigens, CD | 2 | 2015 | 564 | 0.080 |
Why?
| | Caspase 3 | 1 | 2010 | 242 | 0.080 |
Why?
| | Antiviral Agents | 1 | 2015 | 743 | 0.080 |
Why?
| | Referral and Consultation | 1 | 2016 | 839 | 0.080 |
Why?
| | Viremia | 1 | 2010 | 158 | 0.080 |
Why?
| | Vascular Surgical Procedures | 1 | 2013 | 343 | 0.080 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1502 | 0.080 |
Why?
| | Rosaniline Dyes | 3 | 2007 | 15 | 0.080 |
Why?
| | Colitis, Ulcerative | 1 | 2011 | 143 | 0.080 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 6032 | 0.070 |
Why?
| | Double-Blind Method | 4 | 2014 | 2017 | 0.070 |
Why?
| | Odds Ratio | 3 | 2019 | 1057 | 0.070 |
Why?
| | Cell Transplantation | 1 | 2009 | 39 | 0.070 |
Why?
| | Escherichia coli | 1 | 2014 | 849 | 0.070 |
Why?
| | Genomics | 2 | 2025 | 834 | 0.070 |
Why?
| | Immunoglobulins | 2 | 2023 | 163 | 0.070 |
Why?
| | Paracrine Communication | 1 | 2009 | 68 | 0.070 |
Why?
| | Radiotherapy, Conformal | 1 | 2009 | 74 | 0.070 |
Why?
| | Phenotype | 5 | 2019 | 3182 | 0.070 |
Why?
| | Hyalin | 1 | 2008 | 4 | 0.070 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2008 | 29 | 0.070 |
Why?
| | Dermatofibrosarcoma | 1 | 2008 | 7 | 0.070 |
Why?
| | Prosthesis Implantation | 1 | 2010 | 155 | 0.070 |
Why?
| | ROC Curve | 2 | 2024 | 607 | 0.070 |
Why?
| | Neoplastic Stem Cells | 1 | 2012 | 410 | 0.070 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1178 | 0.070 |
Why?
| | Age Factors | 3 | 2019 | 3288 | 0.070 |
Why?
| | Gastrostomy | 1 | 2010 | 126 | 0.070 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2024 | 726 | 0.070 |
Why?
| | Interleukin-4 | 2 | 2007 | 212 | 0.070 |
Why?
| | DNA Mutational Analysis | 3 | 2016 | 408 | 0.070 |
Why?
| | Chemokine CXCL12 | 1 | 2008 | 89 | 0.070 |
Why?
| | ras Proteins | 1 | 2009 | 155 | 0.070 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2008 | 82 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 957 | 0.070 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2023 | 270 | 0.070 |
Why?
| | Logistic Models | 4 | 2016 | 2095 | 0.070 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 1 | 2007 | 17 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2024 | 3614 | 0.060 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 79 | 0.060 |
Why?
| | Interleukin-1beta | 2 | 2019 | 396 | 0.060 |
Why?
| | Career Mobility | 1 | 2007 | 70 | 0.060 |
Why?
| | Kidney Failure, Chronic | 1 | 2013 | 596 | 0.060 |
Why?
| | Deoxycytidine | 1 | 2008 | 218 | 0.060 |
Why?
| | Interleukin-6 | 4 | 1999 | 791 | 0.060 |
Why?
| | alpha-Defensins | 1 | 2006 | 11 | 0.060 |
Why?
| | Length of Stay | 3 | 2019 | 1312 | 0.060 |
Why?
| | DNA, Bacterial | 2 | 2019 | 341 | 0.060 |
Why?
| | Anticoagulants | 1 | 2012 | 718 | 0.060 |
Why?
| | Immunohistochemistry | 5 | 2008 | 1733 | 0.060 |
Why?
| | New York | 2 | 2023 | 125 | 0.060 |
Why?
| | Laparotomy | 1 | 2007 | 113 | 0.060 |
Why?
| | Watchful Waiting | 2 | 2018 | 86 | 0.060 |
Why?
| | Phylogeny | 2 | 2024 | 1011 | 0.060 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 20 | 0.060 |
Why?
| | History, 20th Century | 1 | 2007 | 327 | 0.060 |
Why?
| | Liquid Biopsy | 1 | 2025 | 13 | 0.060 |
Why?
| | Vascular Patency | 1 | 2026 | 120 | 0.060 |
Why?
| | Blood Transfusion | 1 | 2009 | 405 | 0.060 |
Why?
| | Pandemics | 2 | 2025 | 1675 | 0.060 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2005 | 51 | 0.060 |
Why?
| | Critical Care | 1 | 2012 | 693 | 0.060 |
Why?
| | Interleukin-17 | 2 | 2019 | 124 | 0.060 |
Why?
| | Proto-Oncogene Proteins | 1 | 2009 | 628 | 0.060 |
Why?
| | Lipopolysaccharides | 1 | 2009 | 873 | 0.060 |
Why?
| | Neoplasm Proteins | 2 | 2024 | 443 | 0.060 |
Why?
| | Collagen | 1 | 2008 | 467 | 0.060 |
Why?
| | Cell Division | 2 | 2005 | 780 | 0.060 |
Why?
| | Immunity, Cellular | 1 | 2007 | 273 | 0.060 |
Why?
| | Quality Control | 1 | 2025 | 165 | 0.060 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2016 | 59 | 0.060 |
Why?
| | Culture Media | 1 | 2005 | 160 | 0.060 |
Why?
| | Thoracic Neoplasms | 1 | 2005 | 39 | 0.060 |
Why?
| | Mice, Inbred Strains | 1 | 2005 | 399 | 0.050 |
Why?
| | Chromones | 1 | 2024 | 43 | 0.050 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2024 | 29 | 0.050 |
Why?
| | Nitric Oxide | 2 | 2001 | 903 | 0.050 |
Why?
| | Obesity, Morbid | 1 | 2008 | 278 | 0.050 |
Why?
| | Faculty, Medical | 1 | 2007 | 294 | 0.050 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2024 | 39 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2005 | 2847 | 0.050 |
Why?
| | Morpholines | 1 | 2024 | 128 | 0.050 |
Why?
| | Azepines | 1 | 2024 | 106 | 0.050 |
Why?
| | Age of Onset | 1 | 2025 | 543 | 0.050 |
Why?
| | Surgical Procedures, Operative | 1 | 2006 | 266 | 0.050 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 63 | 0.050 |
Why?
| | Quality Improvement | 1 | 2012 | 1268 | 0.050 |
Why?
| | Carcinoma, Renal Cell | 1 | 2026 | 233 | 0.050 |
Why?
| | Fellowships and Scholarships | 1 | 2007 | 346 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 23 | 0.050 |
Why?
| | Toll-Like Receptor 4 | 1 | 2005 | 277 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 37 | 0.050 |
Why?
| | Neoplasm Invasiveness | 2 | 2018 | 515 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2024 | 246 | 0.050 |
Why?
| | Leadership | 1 | 2007 | 404 | 0.050 |
Why?
| | Pseudomonas aeruginosa | 1 | 2025 | 349 | 0.050 |
Why?
| | Multilocus Sequence Typing | 1 | 2022 | 17 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 173 | 0.050 |
Why?
| | Antigens, CD1 | 2 | 2015 | 60 | 0.050 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2023 | 44 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 181 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 110 | 0.050 |
Why?
| | Axilla | 2 | 2017 | 51 | 0.050 |
Why?
| | Body Weight | 4 | 2003 | 993 | 0.050 |
Why?
| | Thymus Gland | 1 | 2023 | 317 | 0.050 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 14 | 0.040 |
Why?
| | Child | 4 | 2019 | 22441 | 0.040 |
Why?
| | Technetium | 1 | 2001 | 10 | 0.040 |
Why?
| | Corticosterone | 1 | 2003 | 244 | 0.040 |
Why?
| | Injections, Intradermal | 1 | 2001 | 11 | 0.040 |
Why?
| | Hypoglycemia | 1 | 2007 | 473 | 0.040 |
Why?
| | Dietary Proteins | 1 | 2003 | 136 | 0.040 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2022 | 83 | 0.040 |
Why?
| | Kidney Neoplasms | 1 | 2026 | 410 | 0.040 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2019 | 258 | 0.040 |
Why?
| | Technetium Tc 99m Sulfur Colloid | 1 | 2001 | 6 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 335 | 0.040 |
Why?
| | NF-kappa B | 1 | 2005 | 668 | 0.040 |
Why?
| | Radionuclide Imaging | 1 | 2001 | 113 | 0.040 |
Why?
| | Propionates | 1 | 2021 | 39 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2021 | 40 | 0.040 |
Why?
| | Leptin | 1 | 2003 | 244 | 0.040 |
Why?
| | Mediastinoscopy | 1 | 2021 | 5 | 0.040 |
Why?
| | Acetates | 1 | 2021 | 82 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 440 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2001 | 184 | 0.040 |
Why?
| | Neoplasm Transplantation | 3 | 2012 | 256 | 0.040 |
Why?
| | Ephrin-B2 | 1 | 2021 | 45 | 0.040 |
Why?
| | Glycoproteins | 2 | 2015 | 357 | 0.040 |
Why?
| | Cholangiography | 1 | 2000 | 10 | 0.040 |
Why?
| | Positron-Emission Tomography | 3 | 2008 | 318 | 0.040 |
Why?
| | Veterans | 1 | 2013 | 1586 | 0.040 |
Why?
| | Workload | 1 | 2002 | 167 | 0.040 |
Why?
| | Precision Medicine | 2 | 2016 | 450 | 0.040 |
Why?
| | Acetylation | 1 | 2021 | 245 | 0.040 |
Why?
| | Probability | 1 | 2001 | 305 | 0.040 |
Why?
| | Early Detection of Cancer | 1 | 2025 | 452 | 0.040 |
Why?
| | Thoracoscopy | 1 | 2020 | 60 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2025 | 1327 | 0.040 |
Why?
| | Radiopharmaceuticals | 1 | 2001 | 191 | 0.040 |
Why?
| | DNA Methylation | 1 | 2025 | 673 | 0.040 |
Why?
| | Tissue Banks | 1 | 2020 | 17 | 0.040 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 431 | 0.040 |
Why?
| | Esophageal Mucosa | 1 | 2020 | 22 | 0.040 |
Why?
| | Regression Analysis | 2 | 2019 | 1003 | 0.040 |
Why?
| | Quality of Health Care | 3 | 2012 | 649 | 0.040 |
Why?
| | Interleukin-12 Subunit p35 | 1 | 2019 | 3 | 0.040 |
Why?
| | Coloring Agents | 2 | 2012 | 93 | 0.040 |
Why?
| | Body Mass Index | 1 | 2008 | 2439 | 0.040 |
Why?
| | Image-Guided Biopsy | 1 | 2019 | 41 | 0.040 |
Why?
| | Fibroblasts | 1 | 2005 | 1035 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2021 | 155 | 0.040 |
Why?
| | Eating | 2 | 2003 | 388 | 0.040 |
Why?
| | Radiography | 2 | 2016 | 838 | 0.040 |
Why?
| | Margins of Excision | 1 | 2019 | 50 | 0.040 |
Why?
| | Paclitaxel | 2 | 2012 | 256 | 0.040 |
Why?
| | Imaging, Three-Dimensional | 2 | 2016 | 577 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2012 | 1308 | 0.040 |
Why?
| | Tight Junctions | 1 | 2019 | 81 | 0.040 |
Why?
| | Organ Size | 2 | 2016 | 469 | 0.040 |
Why?
| | Montana | 1 | 2018 | 20 | 0.040 |
Why?
| | United States Environmental Protection Agency | 1 | 2018 | 28 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 145 | 0.040 |
Why?
| | Mitogens | 1 | 1998 | 56 | 0.040 |
Why?
| | Patient Satisfaction | 1 | 2022 | 700 | 0.030 |
Why?
| | Keratins | 2 | 2010 | 172 | 0.030 |
Why?
| | Interleukin-18 | 1 | 2019 | 237 | 0.030 |
Why?
| | Immunotherapy, Adoptive | 1 | 2022 | 381 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 124 | 0.030 |
Why?
| | Evidence-Based Medicine | 1 | 2002 | 711 | 0.030 |
Why?
| | Cachexia | 1 | 1999 | 74 | 0.030 |
Why?
| | Pedigree | 1 | 2019 | 512 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 541 | 0.030 |
Why?
| | Jejunostomy | 1 | 1997 | 12 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2018 | 199 | 0.030 |
Why?
| | Perioperative Period | 1 | 2017 | 69 | 0.030 |
Why?
| | Dinoprostone | 1 | 1998 | 180 | 0.030 |
Why?
| | Antigen-Presenting Cells | 1 | 2017 | 163 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 1493 | 0.030 |
Why?
| | Occipital Bone | 1 | 2017 | 18 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 122 | 0.030 |
Why?
| | Liver Circulation | 1 | 2016 | 12 | 0.030 |
Why?
| | Parotid Gland | 1 | 2017 | 16 | 0.030 |
Why?
| | Candidiasis | 1 | 1997 | 64 | 0.030 |
Why?
| | Femoral Fractures | 1 | 1998 | 82 | 0.030 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 2016 | 37 | 0.030 |
Why?
| | DNA, Ribosomal | 1 | 2017 | 94 | 0.030 |
Why?
| | Robotic Surgical Procedures | 1 | 2019 | 177 | 0.030 |
Why?
| | Operative Time | 1 | 2017 | 178 | 0.030 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 243 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2020 | 626 | 0.030 |
Why?
| | Infection Control | 1 | 1998 | 173 | 0.030 |
Why?
| | Radiotherapy Dosage | 2 | 2008 | 283 | 0.030 |
Why?
| | Neck | 1 | 2017 | 109 | 0.030 |
Why?
| | Costs and Cost Analysis | 1 | 1997 | 215 | 0.030 |
Why?
| | Models, Anatomic | 1 | 2016 | 84 | 0.030 |
Why?
| | Superinfection | 1 | 2016 | 7 | 0.030 |
Why?
| | Receptors, CXCR5 | 1 | 2016 | 27 | 0.030 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2008 | 219 | 0.030 |
Why?
| | Hydrogen Peroxide | 1 | 1998 | 340 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 439 | 0.030 |
Why?
| | Host Specificity | 1 | 2016 | 35 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 991 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 445 | 0.030 |
Why?
| | Histones | 1 | 2021 | 655 | 0.030 |
Why?
| | Incidental Findings | 1 | 2016 | 80 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2016 | 173 | 0.030 |
Why?
| | Protein Binding | 1 | 2022 | 2261 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 98 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2017 | 530 | 0.030 |
Why?
| | Prevotella | 1 | 2015 | 26 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2015 | 191 | 0.030 |
Why?
| | Virion | 1 | 2015 | 115 | 0.030 |
Why?
| | Endoscopy, Digestive System | 1 | 2016 | 137 | 0.030 |
Why?
| | Qualitative Research | 1 | 2022 | 1626 | 0.030 |
Why?
| | Autoimmune Diseases | 1 | 2019 | 464 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 748 | 0.030 |
Why?
| | Sexual Behavior | 1 | 2019 | 490 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2017 | 5761 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1998 | 435 | 0.030 |
Why?
| | Feasibility Studies | 2 | 2010 | 1065 | 0.030 |
Why?
| | CD40 Antigens | 1 | 2015 | 90 | 0.030 |
Why?
| | Glucocorticoids | 1 | 1999 | 539 | 0.030 |
Why?
| | Mitotic Index | 1 | 2014 | 25 | 0.030 |
Why?
| | Cell Cycle | 1 | 2017 | 632 | 0.030 |
Why?
| | Nausea | 1 | 2014 | 111 | 0.030 |
Why?
| | Cattle | 1 | 2016 | 1004 | 0.030 |
Why?
| | Vomiting | 1 | 2014 | 130 | 0.030 |
Why?
| | Patient Readmission | 1 | 2019 | 724 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 828 | 0.030 |
Why?
| | Colitis | 1 | 2016 | 280 | 0.020 |
Why?
| | Caspase 1 | 1 | 2014 | 149 | 0.020 |
Why?
| | CD4 Lymphocyte Count | 1 | 2014 | 275 | 0.020 |
Why?
| | Phosphorylation | 1 | 1998 | 1761 | 0.020 |
Why?
| | Autoantigens | 1 | 2016 | 429 | 0.020 |
Why?
| | Genes, Immunoglobulin Heavy Chain | 1 | 2013 | 9 | 0.020 |
Why?
| | Cell Lineage | 1 | 2015 | 376 | 0.020 |
Why?
| | Clinical Decision-Making | 1 | 2016 | 345 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 2008 | 3834 | 0.020 |
Why?
| | Inflammation | 2 | 2019 | 2893 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2021 | 3392 | 0.020 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 28 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1525 | 0.020 |
Why?
| | HIV Envelope Protein gp120 | 1 | 2013 | 61 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 30 | 0.020 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2013 | 85 | 0.020 |
Why?
| | Endarterectomy, Carotid | 1 | 2013 | 59 | 0.020 |
Why?
| | Antibody Specificity | 1 | 2013 | 185 | 0.020 |
Why?
| | AIDS Vaccines | 1 | 2013 | 54 | 0.020 |
Why?
| | International Agencies | 1 | 2012 | 31 | 0.020 |
Why?
| | Hemorrhage | 1 | 1998 | 799 | 0.020 |
Why?
| | Thoracotomy | 1 | 2012 | 83 | 0.020 |
Why?
| | Response Elements | 1 | 2012 | 87 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 219 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2013 | 392 | 0.020 |
Why?
| | Homeostasis | 1 | 2016 | 638 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 330 | 0.020 |
Why?
| | Neoplasm Grading | 1 | 2013 | 309 | 0.020 |
Why?
| | APACHE | 1 | 2012 | 65 | 0.020 |
Why?
| | Calcium | 1 | 1998 | 1181 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 299 | 0.020 |
Why?
| | Blood Coagulation Tests | 1 | 2012 | 71 | 0.020 |
Why?
| | Internship and Residency | 1 | 2002 | 1245 | 0.020 |
Why?
| | Receptors, HIV | 1 | 2011 | 24 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 377 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 202 | 0.020 |
Why?
| | Species Specificity | 1 | 2013 | 573 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 779 | 0.020 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2013 | 166 | 0.020 |
Why?
| | Clinical Competence | 1 | 2019 | 1226 | 0.020 |
Why?
| | Bone Marrow | 1 | 2013 | 303 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 273 | 0.020 |
Why?
| | Models, Animal | 1 | 2013 | 394 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2012 | 308 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1512 | 0.020 |
Why?
| | Genes, bcl-2 | 1 | 2010 | 22 | 0.020 |
Why?
| | Risk | 1 | 2013 | 901 | 0.020 |
Why?
| | Cell Communication | 1 | 2013 | 325 | 0.020 |
Why?
| | CA-19-9 Antigen | 1 | 2010 | 30 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 615 | 0.020 |
Why?
| | Cell Survival | 1 | 2014 | 1110 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1305 | 0.020 |
Why?
| | Universities | 1 | 2013 | 452 | 0.020 |
Why?
| | Gastroscopy | 1 | 2010 | 18 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 645 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 148 | 0.020 |
Why?
| | Factor Xa Inhibitors | 1 | 2012 | 189 | 0.020 |
Why?
| | Incidence | 1 | 1996 | 2845 | 0.020 |
Why?
| | Chronic Disease | 1 | 2015 | 1826 | 0.020 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2009 | 65 | 0.020 |
Why?
| | Keratin-20 | 1 | 2008 | 1 | 0.020 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2008 | 6 | 0.020 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2008 | 12 | 0.020 |
Why?
| | Chloroquine | 1 | 2009 | 54 | 0.020 |
Why?
| | Renal Dialysis | 1 | 2013 | 459 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2013 | 2148 | 0.020 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2008 | 140 | 0.020 |
Why?
| | Liver Regeneration | 1 | 2008 | 47 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2010 | 141 | 0.020 |
Why?
| | Device Removal | 1 | 2010 | 145 | 0.020 |
Why?
| | Chemokine CX3CL1 | 1 | 2008 | 25 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 181 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2013 | 899 | 0.020 |
Why?
| | Premedication | 1 | 2008 | 42 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 54 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2013 | 2914 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2008 | 88 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2008 | 75 | 0.020 |
Why?
| | Program Evaluation | 1 | 2012 | 947 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2008 | 107 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2009 | 267 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 2078 | 0.020 |
Why?
| | Models, Molecular | 1 | 2013 | 1600 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2182 | 0.020 |
Why?
| | Quinazolines | 1 | 2009 | 266 | 0.020 |
Why?
| | Remission Induction | 1 | 2008 | 307 | 0.020 |
Why?
| | Acute Disease | 2 | 2003 | 996 | 0.020 |
Why?
| | Swine | 1 | 2010 | 843 | 0.020 |
Why?
| | DNA Primers | 1 | 2008 | 516 | 0.020 |
Why?
| | Body Composition | 2 | 2003 | 715 | 0.020 |
Why?
| | Lewis X Antigen | 1 | 2006 | 5 | 0.020 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2007 | 226 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 245 | 0.010 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2007 | 185 | 0.010 |
Why?
| | Whole Body Imaging | 1 | 2006 | 26 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1057 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2016 | 4553 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2620 | 0.010 |
Why?
| | Fluorescent Dyes | 1 | 2007 | 327 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2006 | 423 | 0.010 |
Why?
| | Radiotherapy | 1 | 2006 | 208 | 0.010 |
Why?
| | Infant | 1 | 2019 | 9886 | 0.010 |
Why?
| | Patient Discharge | 1 | 2011 | 939 | 0.010 |
Why?
| | Base Sequence | 1 | 2008 | 2186 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 113 | 0.010 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2003 | 59 | 0.010 |
Why?
| | Adrenalectomy | 1 | 2003 | 71 | 0.010 |
Why?
| | Appetite Regulation | 1 | 2003 | 32 | 0.010 |
Why?
| | Drug Implants | 1 | 2003 | 83 | 0.010 |
Why?
| | Colorado | 1 | 2013 | 4578 | 0.010 |
Why?
| | Work Schedule Tolerance | 1 | 2002 | 52 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 364 | 0.010 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2002 | 98 | 0.010 |
Why?
| | Dactinomycin | 1 | 2001 | 25 | 0.010 |
Why?
| | Cycloheximide | 1 | 2001 | 47 | 0.010 |
Why?
| | Peritoneum | 1 | 2001 | 45 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2001 | 251 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2001 | 250 | 0.010 |
Why?
| | Continuity of Patient Care | 1 | 2002 | 286 | 0.010 |
Why?
| | Mifepristone | 1 | 1999 | 64 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 1999 | 34 | 0.010 |
Why?
| | Mice, Inbred DBA | 1 | 1999 | 188 | 0.010 |
Why?
| | Candida albicans | 1 | 1997 | 61 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2001 | 2030 | 0.010 |
Why?
| | Obesity | 1 | 2008 | 3073 | 0.010 |
Why?
| | RNA | 1 | 2001 | 940 | 0.010 |
Why?
| | Attitude of Health Personnel | 1 | 2002 | 1174 | 0.010 |
Why?
| | Injury Severity Score | 1 | 1996 | 598 | 0.010 |
Why?
| | Pregnancy | 1 | 2004 | 7154 | 0.010 |
Why?
| | Kidney | 1 | 1997 | 1483 | 0.000 |
Why?
|
|
McCarter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|